Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses experimenting with Sandalore for hair loss and concerns about its authenticity compared to sandalwood oil. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

The user has been on 1mg finasteride for a year, experiencing low libido and moderate erectile issues. They are considering using Cialis daily with finasteride long term to address these side effects.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

A 21-year-old shared a 7-month update on using 1mg finasteride and minoxidil for hair loss, reporting positive results with no side effects except watery semen. The user initially stopped minoxidil due to inconvenience but resumed it after shedding, and is satisfied with the progress despite some thinning at the crown.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.

A user plans to create a custom topical solution by adding finasteride, caffeine, cetirizine, and melatonin to a minoxidil bottle, questioning the stability and effectiveness of this mix. Concerns include potential crystallization and solution muddiness with added ingredients.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

A 19-year-old is considering whether to continue finasteride at 0.5mg every other day due to concerns about side effects. They are seeking advice on dosage frequency and potential side effects, noting no issues so far.

A user had a failed hair transplant with 2800 FUE grafts at a clinic in Turkey, where finasteride was used, and the procedure was poorly executed by technicians rather than the main surgeon. The user later sought repair from a more experienced doctor, highlighting issues with large clinics that handle multiple patients daily.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

A user shared their positive experience with a 2987 graft hair transplant focused on the hairline, supplemented by finasteride and minoxidil for the mid scalp and crown. They expressed satisfaction with the results and the supportive care received during and after the procedure.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.

Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.